Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

An estimated 828 million adults (420 women, 408 men) had diabetes in 2022, an increase of 630 million since 1990. India (212 ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...